Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab
(D10161)		[4] Abatacept,
Rituximab,
Sarilumab,
Tocilizumab		[4] Tocilizumab ,
Rituximab ,
Abatacept ,
Sarilumab (D10161) 💬		[4] CD80,
CD86,
IL6R,
MS4A1 💬		[25] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬[1] 46 💬
2SARILUMAB
(D10161)		[1] Sarilumab[1] Sarilumab (D10161) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[5] 41, 46, 84, 107, 271 💬
3Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]
(D10161)		[1] Sarilumab[1] Sarilumab (D10161) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 46 💬
4Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1
(D10161)		[1] Sarilumab[1] Sarilumab (D10161) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 84 💬
5Sarilumab SAR153191
(D10161)		[1] Sarilumab[1] Sarilumab (D10161) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 41 💬
6Sarilumab SAR153191 (REGN88)
(D10161)		[1] Sarilumab[1] Sarilumab (D10161) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[2] 46, 107 💬